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Low-density lipoprotein cholesterol (LDL-C) has been extensively evaluated. Prospective cohort
studies, randomized controlled trials, biology, pathophysiology, genetics, and Mendelian ran-
domization studies, have clearly taught us that LDL-C causes atherosclerotic cardiovascular dis-
ease. The newest class of drugs to lower LDL-C, the proprotein convertase subtilisin/kexin
type 9 (PCSK9) monoclonal antibodies, have been found to safely reduce LDL-C approximately
60% when added to high-intensity statin therapy. Because their cost is much greater than that
of the currently available agents, their value has been questioned. In late August, 2017, two
groups assessed the value of this class of drugs looking at cost-effectiveness; however, the
Institute for Clinical and Economic Review and Fonarow and colleagues found disparate results
when assessing PCSK9 valuation. Herein, we review the evolution of LDL-C from hypothesis
to fact, and then attempt to adjudicate the 2 models, shedding light on the complex modeling
process. We find that models of cost-effectiveness are helpful adjuncts to decision making, but
that their conclusions depend on many assumptions. Ultimately, clinician judgment regarding
their clinical benefit, balanced by some estimation of cost, may be more productive to target
the right patients for whom the benefits can be well-justified.
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1 | A BRIEF HISTORY OF LOW-DENSITY
LIPOPROTEIN CHOLESTEROL AND
ATHEROSCLEROTIC CARDIOVASCULAR
DISEASE CAUSATION
To fully grasp the current debate regarding valuation of proprotein
convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies
(mabs), one must appreciate the history of low-density lipoprotein
cholesterol (LDL-C). Cholesterol was discovered over 200 years ago,
but it was not until 1913 that a Russian medical student, Nikolai
Anitschkow, demonstrated the association of cholesterol and athero-
sclerosis.1 Twenty-six years later, Michael Macheboeuf identified dis-
tinct lipoproteins, but again the pathogenic/cholesterol connection
lagged.2 Then, in 1939, Carl Müller identified the first cases of familial
hypercholesterolemia (FH), introducing genetics as a participant in
cholesterol regulation.3 His patients had extremely high cholesterol,
fatty collections beneath their skin, and early onset heart disease.
The cholesterol-atherosclerosis link was bolstered. A decade later, in
1949, John Gofman took the cholesterol story to a more granular
level by using analytic ultracentrifugation to separate disparate lipo-
protein particles.4 One was low-density lipoprotein (LDL). Gofman
did not stop there; he demonstrated that patients with FH had not
just high cholesterol levels, but more precisely, extremely elevated
LDL-C. It was not until the 1960s that LDL-C became systematically
studied.5
The Framingham Heart Study, which started in 1948, was the
first of such analyses. Subsequently, numerous other prospective
cohort studies demonstrated concordant associations of LDL-C and
atherosclerotic cardiovascular disease (ASCVD); the higher the LDL-C
the more prevalent the ASCVD, whereas the lower the LDL-C, the
Received: 21 December 2017 Revised: 5 February 2018 Accepted: 6 February 2018
DOI: 10.1002/clc.22924
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the
original work is properly cited and is not used for commercial purposes.
© 2018 The Authors. Clinical Cardiology published by Wiley Periodicals, Inc.
544 wileyonlinelibrary.com/journal/clc Clinical Cardiology. 2018;41:544–550.
less prevalent. These trials fueled more conclusive ones, the random-
ized controlled trials. The Scandinavian Simvastatin Survival Study,
published in 1994, was a turning point for LDL's causal association
with ASCVD.6 In this placebo-controlled trial, over 5.4 years there
was a compelling 30% relative risk reduction in cardiovascular
(CV) mortality, an absolute 9% reduction (i.e., number needed to treat
[NNT] = 11) in the composite triple endpoint of CV death, nonfatal
myocardial infarction (MI), and nonfatal stroke, and a 30% reduction
in all-cause mortality. The Cholesterol Treatment Trialists Collabora-
tion (CTTC) meta-analysis of 26 trials documented that for every mil-
limole per liter reduction in LDL-C, a consistent 22% relative risk
reduction in ASCVD events followed,8 which became the backbone
of the American College of Cardiology (ACC)/American Heart Associ-
ation (AHA) 2013 cholesterol guidelines.9 Over the past decade, we
have also seen a uniformity of results in Mendelian randomization
studies evaluating LDL-C and ASCVD.10 Consistently, mutations that
cause high LDL-C result in a higher prevalence of ASCVD, whereas
mutations causing low LDL-C result in the opposite. In 2017, the
European Atherosclerosis Society published a consensus statement
that concluded: “Consistent evidence from numerous and multiple
different types of clinical and genetic studies unequivocally estab-
lishes that LDL causes ASCVD.”11
2 | PCSK9, FROM DISCOVERY TO DRUG
In 1973, amid our burgeoning appreciation of LDL's role in athero-
sclerosis, Brown and Goldstein published their seminal work describ-
ing the role of the LDL receptor.7 Their model helped clinicians and
scientists not only better understand familial hypercholesterolemia
(FH), but also pursue more appropriate therapeutics to lower LDL-C
and thereby diminish ASCVD risk. Their discoveries led to a Nobel
prize in 1985. In 2003, Abifadel identified the gene for PCSK9, resid-
ing on the short arm of chromosome 1.12 Nearly concurrently, Abifa-
del also demonstrated PCSK9 gain of function mutations causing
high LDL-C, increased ASCVD, and FH.13 Subsequently the opposite
was identified, which was PCSK9 loss of function mutations leading
to low LDL-C and decreased ASCVD.14 The stage was set for inten-
sive further research into PCSK9 as a key LDL-C regulator and a
potential therapeutic target. Though PCSK9 is released by hepato-
cytes as a zymogen, it rapidly undergoes intra-endoplasmic reticulum
autocatalysis to become the active protein that binds hepatocyte LDL
receptors. This binding curtails the repetitive recycling of LDL recep-
tors, leading to higher circulating LDL-C.15 Thus, blocking PCSK9
promised to lead to greater numbers of hepatic LDL receptors, lower
LDL-C, and fewer ASCVD events. In 2007, industry scientists solved
PCSK9’s crystal structure, and in 2010 human studies with PCSK9
mab were initiated.16,17
Just 5 years later, enough convincing data had accrued from mul-
tiple phase 2 and 3 studies such as the ODYSSEY trials: LONG TERM
(Long-term Safety and Tolerability of Alirocumab in High Cardiovas-
cular Risk Patients with Hypercholesterolemia Not Adequately Con-
trolled with Their Lipid Modifying Therapy), FH I and II (Efficacy and
Safety of Alirocumab [SAR236553/REGN727] Versus Placebo on
Top of Lipid-Modifying Therapy in Patients With Heterozygous
Familial Hypercholesterolemia Not Adequately Controlled With Their
Lipid-Modifying Therapy), HIGH FH (Efficacy and Safety of
Alirocumab [SAR236553/REGN727] Versus Placebo on Top of Lipid-
Modifying Therapy in Patients With Heterozygous Familial Hyper-
cholesterolemia); and COMBO 1 (Efficacy and Safety of Alirocumab
[SAR236553/REGN727] Versus Ezetimibe on Top of Statin in High
Cardiovascular Risk Patients With Hypercholesterolemia), LAPLACE
(LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition
Combined With Statin Therapy), RUTHERFORD (Reduction of LDL-C
With PCSK9 Inhibition in Heterozygous Familial Hypercholesterol-
emia Disorder Study), DESCARTES (Durable Effect of PCSK9 Anti-
body Compared with Placebo Study), and TESLA (Trial Evaluating
PCSK9 Antibody in Subjects With LDL Receptor Abnormalities), for
the Food and Drug Administration (FDA) to approve 2 PCSK9 mabs,
alirocumab and evolocumab.18–24
3 | FDA APPROVAL OF ALIROCUMAB AND
EVOLOCUMAB, WHAT ARE THE
INDICATIONS
In 2015, the FDA approved the PCSK9 mabs alirocumab and evolo-
cumab. Evolocumab received approval for homozygous FH, whereas
both drugs were approved for heterozygous FH and clinical ASCVD.
The stipulations for use required that eligible patients were taking
maximally tolerated statin therapy yet still required additional lower-
ing of LDL-C. On its face, these criteria seemed self-evident. What
ensued proved otherwise.
Within the first 6 months following approval, denial rates for
these medications were unprecedented, topping 80% in some ana-
lyses of claims.25 The prior authorization (PA) and appeal processes
were also exceptionally burdensome. A thorough evaluation of
PCSK9 mabs claims and denials ensued. Evidence accrued illustrating
flaws in the utilization management process, inconsistent adjudica-
tion, and a faulty initial review process.26,27 Perhaps most concerning
of all were case reports in the New York Times, Reuters, Bloomberg,
and the Wall Street Journal of incontrovertibly inappropriate PCSK9
mab denials.28–31
In response to such overwhelming evidence, the American Soci-
ety for Preventive Cardiology (ASPC) crafted an initiative including
members from other societies—the FH Foundation, the American
Association of Clinical Endocrinology (AACE), the National Lipid Asso-
ciation (NLA), and the American College of Cardiology (ACC)—to hold
a series of town hall meeting designed to acquire input from all stake-
holders involved in PCSK9 mab therapies. Patients, politicians, payers,
clinicians, the media, and others were invited. A comprehensive paper
was subsequently published, which defined the 5 central designations
in the PCSK9 mab package inserts and produced simple, user-
friendly, single page PA and appeal letters.32 Clarifying and streamlin-
ing the process of prescribing these agents was the intent of this
open-access paper and its attachments. To date, nearly 1000 clini-
cians have attended these town halls or utilized the consensus paper.
Still, access to PCSK9 mab remains problematic.
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4 | FOURIER AND THE NEW CV EVENT
REDUCTION INDICATION
FOURIER (Further Cardiovascular Outcomes Research With PCSK9
Inhibition in Subjects With Elevated Risk) was designed to assess the
effect of evolocumab on clinical outcomes. It randomized 27,564
high-risk individuals on high-intensity statin therapy with LDL-
C ≥ 70 mg/dL to either placebo or evolocumab.33 Evolucumab
produced a 59% LDL-C reduction and led to a 15% reduction in the
primary endpoint of cardiovascular death, nonfatal MI, or stroke,
unstable angina, and coronary revascularization. The key secondary
endpoint of CV death, nonfatal MI, and nonfatal stroke was reduced
by 20%. At 3 years, there was an absolute risk reduction of 2% in
both primary and key secondary endpoints, translating into an NNT
over 3 years of 50. The findings were consistent with the CTTC's
results. Additionally, from a safety perspective, no adverse signals
were found in FOURIER, even in the realm of neurocognitive events
as demonstrated in the large parallel study, EBBINGHAUS (Evaluating
PCSK9 Binding Antibody Influence on Cognitive Health in High Car-
diovascular Risk Subjects).34
With these data, the FDA granted a new indication for CV event
reduction for evolocumab in late 2017; however, regarding utilization,
little seems to have changed.
5 | INSTITUTE FOR CLINICAL AND
ECONOMIC REVIEW: ITS MISSION AND
INFLUENCE ON PCSK9 MAB UTILIZATION
The Institute for Clinical and Economic Review (ICER) is an organiza-
tion that states on its website35: “ICER is driven by a mission to con-
duct evidence-based reviews of health care interventions, such as
drug, devices and diagnostics, that help patients, doctors, and every-
one else in the health care system know what works. For every
report, ICER follows a process that includes numerous opportunities
for stakeholders to engage and be involved throughout its develop-
ment.” Although this is a noble mission that does not appear to speak
about costs, their reports focus on the dollar value of medical
interventions.
ICER's non–peer-reviewed PCSK9 Inhibitor New Evidence
Update focused on their interpretation of FOURIER. Some findings
were scientifically valid and deserve recognition.36 ICER acknowl-
edged FOURIER's excellent quality and convincing demonstration of
the lack of safety concerns. It also acknowledged that other drugs,
such as ezetimibe, can reduce CV events by lowering LDL-C as seen
in the IMPROVE IT (Examining Outcomes in Subjects With Acute
Coronary Syndrome: Vytorin [Ezetimibe/Simvastatin] vs Simvastatin
[P04103]) trial.39 Finally, ICER invited individuals and groups to
express their opinions regarding the implications of FOURIER. This
process not only required a significant time commitment from those
of us who spoke with ICER, but also from ICER itself. For these rea-
sons, they should be commended.
However, we believe that ICER made 4 key miscalculations in
their analysis. The first and most consequential was their C+ rating:
“We considered a B+ rating (incremental or better), but the
uncertainty introduced by the non-significant trend towards
increased cardiovascular mortality in years 2+ of the trial (HR 1.12,
95% CI 0.88-1.42) led us to the more conservative assessment.”
ICER's C+ rating claims that compared with the standard of care in
high-risk patients, evolocumab is comparable or better, whereas a B+
rating would have recognized that FOURIER proved evolocumab to
be incremental or better.” It is hard to dispute that FOURIER's results
demonstrate evolocumab to be at least incremental to or better than
standard of care, an easy ICER B+ rating.
ICER said that their reason for downgrading the PCSK9 mab
class hinged partly on FOURIER mortality data from a landmark anal-
ysis, which includes only a portion of the data. A landmark analysis
excludes patients with events before the start of the landmark curves
and does not include all patients or all events. As such, it is observa-
tional and not fully randomized. Therefore, though valuable, it cannot
be relied on to make any definitive assessments. Furthermore, the
overall mortality data are neutral. This is expected, because no prior
intervention when added to statins has reduced mortality, not high-
intensity statins or ezetimibe, or most recently anacetrapib.8,40,41
Only when compared with placebo have statins shown a mortality
benefit. To make a scientific claim about these partial mortality
results of only 2-year plus analysis is not scientific. Additionally, the
trial was not powered for mortality. It was too short to demonstrate
a mortality benefit, and the confidence intervals for mortality were
too large to infer any scientific conclusion. Most importantly, mortal-
ity cannot be the only endpoint that proves a drug's effectiveness.
Consider this: the 2013 ACC/AHA cholesterol guidelines hinge on
CTTC results.8,9 Only 3 of the 26 trials in the CTTC demonstrated
mortality benefits. They were powered to do so, far longer in dura-
tion than FOURIER, and placebo controlled. The 23 remaining trials
compared different doses or types of statins and demonstrated
reductions in nonfatal events, not mortality. Statin therapy as recom-
mended in the 2013 ACC/AHA cholesterol guidelines is based
entirely on these trials, the overwhelming majority of which failed to
show mortality benefits of statins. Thus, adopting ICER's mortality-
reliant logic in appraising FOURIER would demand that we dismiss
the relevance of all statin trials supporting higher vs lower doses, and
negate the 2013 ACC/AHA cholesterol guidelines.
ICER also downplayed the importance of nonfatal MI and stroke.
It is now recognized that reductions in nonfatal MI and stroke ulti-
mately translate into downstream mortality benefits. Perhaps more
important though is the fact that such events can result in not only
life-altering morbidities for patients, they can also permanently
adversely affect patients' relatives/caretakers. To reiterate, mortality
cannot be the sole endpoint considered; other infirmities do evoke
grave consequences. Finally, there is an irony in ICER's insistence that
mortality reduction is a prerequisite to support the B+ rating that
they refused to grant this drug class. Mortality could not be demon-
strated in FOURIER in part because the trial was brief, its brevity
being the consequence of an unexpectedly high residual ASCVD risk
in the placebo arm. FOURIER thus proves that ASCVD patients need
more intensive therapies because their residual risk remains unac-
ceptably high. In a way, FOURIER's lack of a mortality benefit demon-
strates just how important it is for appropriate high-risk patients to
take the PCSK9 mabs.
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The explanation for poor uptake of a PCSK9 mab was also dis-
torted in the ICER report. Their statement, “Uptake of the PCSK9 inhib-
itors has been slow, with their high cost and limited data on hard CV
disease outcomes dampening enthusiasm for the drugs” has limited
support. Instead, multiple studies, even cited in their update, have dem-
onstrated flaws in utilization management, adjudication, and initial
review processes.25–27 Various sources have cited barriers in accessing
the PCSK9 mab. Doctors enthusiastically prescribe these medicines but
are stymied by time-consuming oppressive obstacles. The media has
spotlighted individual cases, whereas others have examined large data-
sets. The New York Times, for example, revealed the case of a 41-year-
old man with severe FH. Having had a first MI at age 17 years, fol-
lowed by coronary artery bypass surgery, multiple stents, and the need
for prolonged LDL apheresis, this gentleman had a persistent LDL-C
well over 200 mg/dL on maximally tolerated statin therapy, ezetimibe,
and a bile acid sequestrant.28 He was an indisputable candidate for a
PCSK9 mab. Yet it took a year and the help of a New York Times
expose to get him the medicine he needed and deserved. The FH
Foundation demonstrated that even in FH patients with ASCVD and
extremely high LDL-C on maximally tolerated statin therapy, there is an
unacceptably high number of PCSK9 mab denials.27 Others have stud-
ied large claims databases, demonstrating the lack of disparity in drug
rejections among those on diverse statin regimens, with or without dia-
betes, and even with or without ASCVD (using prescription antiplatelet
therapy as an ASCVD proxy).26 The approval process, therefore,
appears to be unpredictable. The FH foundation, ASPC, AACE, and
others have published these findings in well-respected peer-reviewed
journals.32 A consistency of conclusions provides further credence to
the claim that the process of drug approval/denial is seriously flawed.
6 | MODELING COST-EFFECTIVENESS OF
MEDICATIONS
The purpose of economic models assessing drugs is to derive two
metrics, QALY and ICER (N.B. ICER the metric is different from ICER
the Institute).38 These terms, though different, are frequently inap-
propriately interchanged. QALY, Quality Adjusted Life Years, is a
number expressing two variables, quality and quantity of life. Its value
hinges on another metric, Utility. Utility is the numeric expression of
an individual’s health. It ranges from 0 to 1; 0 being death, and 1, per-
fect health. The average US citizen has a utility of 0.825, meaning he
or she enjoys 82.5% of perfect health. A QALY therefore expresses
both the quality and time added to one’s life by a novel therapy. A
QALY is calculated by multiplying the extra time derived from a ther-
apy by the Utility a person experiences during that time.
An ICER, or Incremental Cost Effectiveness Ratio, provides the
relationship between the cost and benefit of two different interven-
tions. ICER is a monetary figure, while QALY is not. The formula to
derive an ICER is (c1-c2)/(q1-q2), where c1 is the average healthcare
cost of treatment for patients on a new drug, and c2 is the average
healthcare cost of treatment on standard therapy. Q1 is the new
drug’s QALY, while Q2 is the QALY with standard care. ICER, the
incremental cost effectiveness ratio, is the cost of a new therapy
required to provide a person with an additional year of perfect health.
A calculated ICER is compared to an “acceptable” ICER threshold to
determine whether a novel therapy is worth its price tag. Unfortu-
nately, this “acceptable” value is subjective; there is yet to be an
agreed-upon number. In first world countries, WHO recommends 3
times of the GDP be used as the threshold.39 For example, in the US,
that is approximately $150,000, although the threshold can vary from
$50,000 to $200,000. To better grasp an ICER’s implications, one must
examine the model itself, and the inputs used to draw conclusions on
a therapy’s cost effectiveness and in so doing, derive an ICER.
7 | REVIEW OF RECENT COST-
EFFECTIVENESS MODELS OF PCSK9
INHIBITORS
There have recently been 2 models of cost-effectiveness of PCSK9
inhibitors published, with an update to 1 analysis. They differ greatly
in their conclusions; 1 noted these agents would not be cost effec-
tive, whereas the other suggested they were close to current thresh-
olds for acceptable cost–benefit.
The ICER analysis (Kazi et al.42) relied on the Coronary Heart Dis-
ease Policy Model published 30 years ago.43 This is in contradistinction
to the model employed by Fonarow et al.,44 which is based on Gandra
et al.,45 Toth et al.,46 and the Repatha Health Technology Assessment
(HTA) submissions, including the one to National Institute for Health
and Care Excellence in the United Kingdom.47 Even at the time of their
original publication, the authors recognized this model's limitations
stating, “The specific forecasts could be inaccurate, however, as a con-
sequence of erroneous assumptions or misestimated baseline data.”
An important input to the cost-effectiveness models is the baseline
event rate. These differed greatly in the 2 analyses: Kazi et al. used an
event rate of 3.7% for MI, stroke, and CV death, whereas Fonarow
et al. used 6.4%. When Fonarow et al. considers revascularization in his
model, the event rate rises to 9.7%.42,44 ICER chose to use an event
rate derived from clinical trials, and also elected to exclude recurrent
events. Fonarow et al. selected real world numbers and included recur-
rent events as they have real world implications. Fonarow et al. used
National Health and Nutrition Examination Survey and MarketScan
data to construct their model. It has been well-established that event
rates are uniformly lower (one-half to one-third) in clinical trials than in
the real world. As the intent of these pharmacoeconomic models
should be to determine whether PCSK9 mabs are cost effective outside
of clinical trials and in the real world, it stands to reason that an optimal
event rate should be real world. Event rates produce a large effect on a
drug's value; low rates make it harder to demonstrate value whereas
high rates do the opposite. Thus, the large disparity of event rates
between these models is consequential. Inputting a spuriously low
event rate diminishes the value of the medication under study.
8 | CHOOSING THE EVENTS THEMSELVES,
ANOTHER POWERFUL PLAYER
In addition to selecting a given event rate to demonstrate treatment
effect, the other substantial driver of model output, one must also
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select the events themselves. Kazi et al. chose nonfatal MI, nonfatal
cerebrovascular accident (CVA), and death. Fonarow et al. added hos-
pitalizations for coronary revascularizations. The latter events not only
drive up healthcare costs for payers, but also take a significant toll on
patients and their caregivers. Again, in a real-world vein, adding such
hospitalizations as events makes sense. Other inputs in the models,
though less impactful on the final output, also require our attention.
The source of utility values for MI and CVA differed between the
studies. Kazi et al. chose values from a Global Burden of Disease
dataset, reflecting third-world figures. Fonarow et al. chose first
world or United States data. Considering just MI and CVA, ICER
assigned utility values of 0.96 and 0.88, respectively. As the average
US citizen has a utility of 0.825, such values are hard to justify.48 It is
difficult to imagine how a stroke victim can enjoy a higher utility, or
quality of life than that of an average healthy individual. Equally
implausible is suggesting that a heart attack victim has a nearly per-
fect quality of life, far exceeding that of an ordinary American. Dis-
utility, the immediate and transient impact of an event, was similarly
minimized by Kazi et al. For MI, their assigned disutility was 0.005,
whereas for CVA it was 0.01. MI and CVA were thus considered by
Kazi et al. to have essentially no meaningful immediate impact, again
a supposition that runs counter to the experience of clinicians and
family members who have cared for heart attack and stroke patients.
Another input into the cost-effectiveness models is the baseline
LDL-C. Kazi et al. used 104 mg/dL, the mean LDL-C, whereas
Fonarow et al. used this scenario, but also one with a higher value, as
more often seen in clinical practice (mean = 130 mg/dL). Neither
model employed scenarios in which LDL-C was very high, as is typi-
cally the case in those with FH. The age of modeled patients also var-
ied between the 2 studies. Kazi et al. used an age range of 40 to
84 years, whereas Fonarow et al. used ≥18 years. By omitting youn-
ger patients, Kazi et al. failed to consider those with FH, many of
whom have events between 18 and 40 years old. Omitting those
over 84 years also fails to recognize another subset at extremely high
risk for ASCVD events, the very elderly.
Finally, the choice of incremental cost-effectiveness ratio thresh-
old varied between the 2 studies. In their base cases, Kazi
et al. selected $100,000 per quality-adjusted life year (QALY),
whereas Fonarow et al. chose $150 000 per QALY. Though the merits
of one number vs another are debatable, Kazi et al. has acknowledged
that in first-world countries, an incremental cost-effectiveness ratio
threshold of $150 000 per QALY can be appropriate. The higher the
incremental cost-effectiveness ratio, the easier it is for a drug to have
value. Thus, the choice of incremental cost-effectiveness ratio is not
inconsequential. Fonarow and colleagues ran several scenario ana-
lyses utilizing different incremental cost-effectiveness ratio thresh-
olds. They also did this with other variables. By doing so, their analysis
helps better inform clinicians about the nuances inherent in medical
practice. When caring for patients, clinicians use population data as a
guide, yet understand that each patient is unique. The multiple scenar-
ios presented by Fonarow et al. help illustrate the importance of con-
sidering each patient in his or her own light. Their models promote
more of a personalized or precision approach to patient.
9 | PRICE TO ACHIEVE COST
EFFECTIVENESS
The Kazi et al. model concluded that an annual drug price of $4215
would be needed to achieve cost-effectiveness at a threshold of $100
000/QALY. Fonarow et al. concluded that an annual net drug price of
$9669 would be required to reach cost-effectiveness at a $150
000/QALY threshold. As the current list price for the PCSK9 mab is
approximately $14 500, it would appear that Fonarow et al. believes
evolocumab is priced too high. A careful read of their article will
reveal, however, that they have already reached that benchmark. The
exact price paid by pharmacy benefit managers is not publicly dis-
closed. Assuming an average 29% rebate cited (PCSK9 mab rebates
may be higher), the drug price would be around $10 000, but if it is
closer to 50%, evolocumab would be very well-priced. Additionally,
though some may argue that the Canadian cost of CV events differs
from that of the United States and therefore should not be used as a
comparator, in Canada, the list price is ~$7000 Canadian dollars, thus
not much different from their model's calculated threshold.
In summary, using different inputs and assumptions, the 2 articles
arrived at very different conclusions. This illustrates how these models
are heavily influenced by the assumptions that go into the models,
and the Kazi et al. model has many questionable assumptions. Hence,
we cannot rely on these as a final and absolute assessment of value.
10 | CONCLUSION
Over the past 30 years, great strides have been made in managing
ASCVD. Perhaps most consequential has been the confirmation that
LDL-C causes ASCVD. We now have 4 classes of drugs that reduce
LDL-C with large randomized trials demonstrating a reduction in
ASCVD risk, reaffirming the central importance of lowering LDL-C.
Two years ago, the PCSK9 mabs alirocumab and evolocumab were
FDA approved for specific indications with their very potent LDL-C
lowering, and most recently 1 agent has been approved for reduction
of CV events. Unfortunately, their uptake has been slow, and a key
reason for this has been the unprecedented pushback from payers and
the pharmacy benefit managers (PBMs). (A recent pushback on PBMs
has been made by the proposed Berkshire Hathaway/Amazon/J.P.
Morgan consortium, but it is much too early to understand what gen-
eralizable impact this may have). The ICER group has played a signifi-
cant role in fostering this challenge, asserting that these medications
are not valuable enough at their current price. Modeling the valuation
of medications is an imperfect science, one based on assumptions that
can vary widely, as seen in the large differences between the 2 recent
publications from Kazi et al. and Fonarow et al..
In the end, we must return to clinical medicine, wherein we need
to examine a drug's clinical benefit for an individual patient. The newer,
more costly therapies should be targeted to those who will benefit
most, and only after other less expensive therapies have failed to meet
risk-reduction goals. Rather than using models to block access for all
patients, payers should work jointly with clinicians, who can identify
those patients who will benefit most. In so doing, we will assure the
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most cost-effective use of this important new class of drugs, and
others that will surely follow, to help reduce the risk from CV disease.
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